Views & Analysis Pharma’s apprentice army is sculpting the future A skills gap has been threatening to knock the shine off the UK biotechnology sector’s sparkling reputation for the last few years.
News FDA clears Nuvation's first product Ibtrozi, for lung cancer Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face